Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 842

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 842
---
 conflict with, or diminishes or impedes, the rights or licenses granted to Aadi under this Agreement;

(n) To WuXi Biologics’ knowledge, the Licensed IP is free and clear of all liens, claims, security interests or other encumbrances
of any kind and, during the Term, [***];

(o) To WuXi Biologics’ knowledge, none of the inventions disclosed in the Licensed
Platform Patents or Licensed ADC Patents were conceived of or reduced to practice using funding from the United States government;

(p) To WuXi Biologics’ knowledge, [***];

G-25

(q) To WuXi Biologics’ knowledge, all necessary consents, approvals and
authorizations of all Regulatory Authorities, other governmental authorities and other persons or entities required to be obtained by WuXi Biologics in order to enter into this Agreement have been obtained;

(r) To WuXi Biologics’ knowledge, [***];

(s) WuXi Biologics [***];

(t) WuXi Biologics has not knowingly withheld any Licensed Know-How [***] for Aadi’s
conduct of activities under this Agreement and, to WuXi Biologics’ knowledge, all Licensed Know-How provided to Aadi is free from any material inaccuracies;

(u) to WuXi Biologics’ knowledge, [***];

(w) neither WuXi Biologics nor any of its Affiliates are, or have been, debarred or disqualified by any Regulatory Authority; and none
of WuXi Biologics or any of its Affiliates’ employees or contractors who were or will be involved in the Development, Manufacture or Commercialization of Licensed ADCs and/or Licensed Products are, or have been, debarred or disqualified by any
Regulatory Authority;

(x) WuXi Biologics has complied with all U.S. and applicable foreign export and reexport control laws and
regulations, including but not limited to the Export Administration Regulations (“EAR”) maintained by the U.S. Department of Commerce and trade and economic sanctions maintained by the U.S. Treasury Department’s Office of
Foreign Assets Control (“OFAC”);

(y) WuXi Biologics has not, directly or indirectly, sold, exported, reexported,
transferred, diverted, or allowed the use of, any Licensed ADCs or Licensed Know-How to any destination, entity or person prohibited by the laws or regulations of the United States or applicable foreign
jurisdictions